Avaleht › Burkitti lümfoom › California

Burkitti lümfoom kliinilised uuringud osariigis California

20 uuringut haiguse Burkitti lümfoom jaoks otsivad osalejaid osariigis California.

Linnad osariigis California

Ametlik uuringutekst (inglise keeles)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Kaiser Permanente Downey Medical Center, Downey
Loma Linda University Medical Center, Loma Linda
Miller Children's and Women's Hospital Long Beach, Long Beach
ja veel 9

VärbamineFaas 2

366 Days – 46 Years · Kõik sood · Uuendatud 2. okt 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Kaiser Permanente-Deer Valley Medical Center, Antioch
Community Cancer Institute, Clovis
UC Irvine Health Cancer Center-Newport, Costa Mesa
ja veel 26

VärbamineFaas 3

Vanused 18–39 · Kõik sood · Uuendatud 2. okt 2026 · NCT03150693

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

City of Hope Comprehensive Cancer Center, Duarte
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
UC San Diego Moores Cancer Center, La Jolla
ja veel 1

VärbamineFaas 2

Vanused 18 ja vanemad · Kõik sood · Uuendatud 29. sept 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Loma Linda University Medical Center, Loma Linda
Miller Children's and Women's Hospital Long Beach, Long Beach
UCSF Benioff Children's Hospital Oakland, Oakland
ja veel 4

VärbamineFaas 2

365 Days · Kõik sood · Uuendatud 25. sept 2026 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

UC Irvine, Orange

VärbamineFaas 3

Vanused 18 ja vanemad · Kõik sood · Uuendatud 21. sept 2026 · NCT07648264

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Children's Hospital Los Angeles ( Site 1006), Los Angeles

VärbamineFaas 1/2

6 Months – 25 Years · Kõik sood · Uuendatud 17. sept 2026 · NCT06395103

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Kaiser Permanente-Anaheim, Anaheim
Kaiser Permanente Downey Medical Center, Downey
Kaiser Permanente-Fontana, Fontana
ja veel 14

VärbamineFaas 2

Vanused 1–30 · Kõik sood · Uuendatud 1. sept 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Kaiser Permanente Downey Medical Center, Downey
City of Hope Comprehensive Cancer Center, Duarte
Loma Linda University Medical Center, Loma Linda
ja veel 14

VärbamineFaas 3

365 Days – 25 Years · Kõik sood · Uuendatud 25. aug 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

Children's Hospital Los Angeles, Los Angeles
Children's Hospital Orange County, Orange
UCSF School of Medicine, San Francisco

VärbamineFaas 2

Vanused 7–25 · Kõik sood · Uuendatud 19. aug 2026 · NCT05082519

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Research Site, Duarte
Research Site, Los Angeles
Research Site, Palo Alto

VärbamineFaas 1/2

Vanused 12 ja vanemad · Kõik sood · Uuendatud 19. aug 2026 · NCT06137118

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Stanford University, Palo Alto

VärbamineFaas 1

Vanused 18 ja vanemad · Kõik sood · Uuendatud 12. aug 2026 · NCT06340737

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

City of Hope, Duarte
Valkyrie Clinical Trials, Los Angeles

VärbamineFaas 1/2

Vanused 13–90 · Kõik sood · Uuendatud 6. aug 2026 · NCT06533579

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

VärbamineFaas 1/2

Vanused 18 ja vanemad · Kõik sood · Uuendatud 31. juuli 2026 · NCT07069699

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

City of Hope Medical Center, Duarte

VärbamineFaas 1

Vanused 12–55 · Kõik sood · Uuendatud 14. juuli 2026 · NCT07133997

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

Research Site, Duarte

VärbamineFaas 1/2

Vanused 12 ja vanemad · Kõik sood · Uuendatud 13. juuli 2026 · NCT07109219

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

University of California, San Francisco, San Francisco

VärbamineFaas 1

Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. juuni 2026 · NCT04545762

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

City of Hope Medical Center, Duarte
City of Hope at Irvine Lennar, Irvine
UC San Diego Moores Cancer Center, La Jolla
ja veel 1

VärbamineFaas 2

Vanused 18–54 · Kõik sood · Uuendatud 17. märts 2026 · NCT06918431

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

City of Hope, Duarte

VärbamineFaas 1

Vanused 18 ja vanemad · Kõik sood · Uuendatud 5. nov 2025 · NCT04260022

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

University of California, Los Angeles (UCLA) - Medical Center, Los Angeles

VärbamineFaas 1/2

Vanused 15–50 · Kõik sood · Uuendatud 9. sept 2025 · NCT04150497

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

City of Hope, Duarte
Children's Hospital Los Angeles, Los Angeles
UCLA Mattel Children's Hospital, Los Angeles
ja veel 2

VärbamineFaas 2

Vanused 1–25 · Kõik sood · Uuendatud 4. mai 2025 · NCT03509961

Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.